soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo In patients with type 2

Providers evaluate potential interactions and risk factors

The weight-loss drugs are ultimately drugs for the brain

We pride ourselves on our expertise, comprehensive wellness solutions, and our strong dedication to improving the health and well-being of every patient we serve

The semaglutide weight management drug market remained anchored to hospital-linked dispensing because initiation often occurred under endocrinology, cardiology, or primary care supervision, especially when comorbid obesity, diabetes, and cardiovascular risk had to be managed together

Hurtado, Maria D., et al

The Case of Vitamin C You can only absorb a limited amount of Vitamin C orally before it causes stomach upset